CN113274540A - 一种氧化亚铜-氧化刺槐豆胶抗菌敷料 - Google Patents

一种氧化亚铜-氧化刺槐豆胶抗菌敷料 Download PDF

Info

Publication number
CN113274540A
CN113274540A CN202110562568.2A CN202110562568A CN113274540A CN 113274540 A CN113274540 A CN 113274540A CN 202110562568 A CN202110562568 A CN 202110562568A CN 113274540 A CN113274540 A CN 113274540A
Authority
CN
China
Prior art keywords
locust bean
bean gum
oxide
cuprous oxide
dressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202110562568.2A
Other languages
English (en)
Inventor
林文浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Shangxin Purification Engineering Co ltd
Original Assignee
Guangzhou Shangxin Purification Engineering Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Shangxin Purification Engineering Co ltd filed Critical Guangzhou Shangxin Purification Engineering Co ltd
Priority to CN202110562568.2A priority Critical patent/CN113274540A/zh
Publication of CN113274540A publication Critical patent/CN113274540A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28Polysaccharides or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/18Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/20Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/44Medicaments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/46Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0087Glucomannans or galactomannans; Tara or tara gum, i.e. D-mannose and D-galactose units, e.g. from Cesalpinia spinosa; Tamarind gum, i.e. D-galactose, D-glucose and D-xylose units, e.g. from Tamarindus indica; Gum Arabic, i.e. L-arabinose, L-rhamnose, D-galactose and D-glucuronic acid units, e.g. from Acacia Senegal or Acacia Seyal; Derivatives thereof
    • C08B37/0093Locust bean gum, i.e. carob bean gum, with (beta-1,4)-D-mannose units in the main chain branched with D-galactose units in (alpha-1,6), e.g. from the seeds of carob tree or Ceratonia siliqua; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/02Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075Macromolecular gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2305/00Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00

Abstract

本发明涉及一种氧化亚铜‑氧化刺槐豆胶抗菌敷料,该敷料由水凝胶基质、分散剂、保湿剂、渗透压调节剂组成,其中敷料由抗菌型敷料基质为氧化亚铜‑氧化刺槐豆胶与κ‑C复配得到,氧化亚铜‑氧化刺槐豆胶由天然刺槐豆胶通过高碘酸钠将半乳甘露聚糖链C2、C3位氧化开环得到二醛结构,Cu2+与醛基发生氧化还原反应得到Cu2O填充在凝胶孔隙中;该抗菌敷料为水凝胶敷料类型,敷料基质具有抗菌效果,可减少防腐剂等使用,并且具有良好的耐水性和保湿性。

Description

一种氧化亚铜-氧化刺槐豆胶抗菌敷料
技术领域
本发明属于医用材料领域,具体涉及一种氧化亚铜-氧化刺槐豆胶抗菌敷料。
技术背景
刺槐豆胶是一种天然的中性半乳甘露聚糖,分子量约30万道尔顿,其结构主要以D-甘露聚糖在1,6位上以β-(1,4)糖苷键连接α-D-吡喃半乳糖,其中半乳糖和甘露糖比例为1:4,是甘露糖含量较多的天然植物籽多糖。天然刺槐豆胶由于其分子量大,几乎没有结晶区,主要用于食品、日化中作为增稠剂使用,但分子中大部分羟基均可作为活泼位点进行改性,进而容易向分子链中引入功能性基团从而赋予本身不具有的功能。
研究表明,氧化亚铜作为中间价态铜化合物,既具有氧化性又具有还原性,与生物蛋白质有较强结合力,抑制蛋白质生长,具有较高的抗菌活性,因此,能开发出有应用价值的抗菌材料。目前,氧化亚铜负载在天然多糖上主要以纤维素为主,但纤维素结晶度很高具有难溶性,改性过程困难,且生物降解性差,因此,将Cu2O负载在溶解性和降解度高的改性刺槐豆胶上,可作为一种新型医药复合抗菌材料。
发明内容
为了解决上述的技术问题,本发明提供了一种氧化亚铜-氧化刺槐豆胶抗菌敷料及其制备方法,另一个目的在于提供一种抗菌敷料的力学性能及抗菌效果参数;
所述的敷料由水凝胶基质、分散剂、保湿剂、渗透压调节剂组成;
所述的水凝胶基质为氧化亚铜-氧化刺槐豆胶与κ-C得到的复配物;
所述的分散剂为直链淀粉、羟丙基淀粉、羟丙基淀粉中的一种或组合;
所述的保湿剂为甘油、丁二醇、丙二醇中的一种或组合;
所述的渗透压调节剂为氯化钠、葡萄糖中的一种或组合。
所述的水凝胶基质结构示意式如(I)所示:
Figure BDA0003079536290000011
Figure BDA0003079536290000021
所述的水凝胶基质的制备步骤为:
1)将0.1~1.0g天然刺槐豆胶和0.5~2.0g的高碘酸钠溶于100~150mL蒸馏水中,在圆底烧瓶中进行反应,用锡箔纸包裹遮光,避免高碘酸钠分解,在室温下磁力搅拌5~8h;将乙二醇加入混合液中搅拌0.5~1.0h,以消除未反应的高碘酸钠,并在30~40℃下干燥,得到氧化刺槐豆胶;
2)将0.1~1.0g氧化刺槐豆胶溶解,浸入到1~5wt%的CuSO4溶液30~90ml中,置于恒温水浴槽中,再加入1~10wt%的KOH溶液30~100ml,搅拌反应一定时间后,投入 0.5~5gκ-C粉末,80~90℃交联0.5~2h,冷却,用蒸馏水反复漂洗,直到漂洗液为中性。
所述的氧化亚铜-氧化刺槐豆胶抗菌敷料的制备方法为:
按重量级百分比计,将0.2~2.0%氧化亚铜-氧化刺槐豆胶加入至去离子水中溶解,磁力搅拌逐渐加热升温至50℃,加入0.5~2%κ-C搅拌分散均匀继续升温至80~90℃,得到水凝胶基质,该温度范围下依次加入0.1~2%分散剂、0.1~0.5%保湿剂和0.1~0.5%渗透压调节剂,其余为去离子水,并保温1.0h,使胶液充分溶胀,采用真空脱气装置对胶液进行高温脱气,除泡0.5h,调节pH为7.3~7.4,并降温至50~60℃,静置24h,即得氧化亚铜-氧化刺槐豆胶抗菌敷料。
所述步骤中的氧化亚铜-氧化刺槐豆胶与κ-C的添加量比为0.5~2.5:1,优选地,添加量比为2:1;
所述步骤中水凝胶基质、分散剂、保湿剂、渗透压调节剂的添加量比可为10:1~5:0.5~2.5:1 优选地,添加量比为10:4:2:1。
与现有技术相比,本发明具有如下有益效果:
本发明的抗菌敷料能够吸收自身115倍的重量,不易脱水收缩,4h内具有良好的保湿性,且对革兰氏阴性、阳性菌中的大肠杆菌和金黄色葡萄球菌的抑制率较好,抑菌圈达到8.5mm 以上,可减少防腐剂等成分的添加。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚明了,下面结合具体实施方式,对本发明进一步详细说明。应该理解,这些描述只是示例性的,而并非要限制本发明的范围。此外,在以下说明中,省略了对公知结构和技术的描述,以避免不必要地混淆本发明的概念。
实施例1
按重量级百分比计,将氧化亚铜-氧化刺槐豆胶加入至去离子水中溶解,磁力搅拌逐渐加热升温至50℃,加入κ-C搅拌分散均匀继续升温至80~90℃,得到固含量为2%的水凝胶基质,该温度范围下依次加入0.8%羟丙基淀粉、0.4%丁二醇和0.2%葡萄糖,其余为去离子水,并保温1.0h,使胶液充分溶胀,采用真空脱气装置对胶液进行高温脱气,除泡0.5h,调节 pH为7.3~7.4,并降温至50~60℃,静置24h,即得氧化亚铜-氧化刺槐豆胶抗菌敷料;
其中氧化亚铜-氧化刺槐豆胶和κ-C粉末的添加量比为0.5~2.5:1,如表1所示:
表1:氧化亚铜-氧化刺槐豆胶和κ-C粉末的添加量
Figure BDA0003079536290000031
对上述五组样品进行脱水收缩、吸水溶胀性、保湿能力以及抗菌率(%)测定,其测定条件如下:
1)脱水收缩:称取一定量的样品置于室温下密封保存,37℃下静置,并在选取的时间段取出凝胶,计算称量前与称量后的质量差△W,实验重复三次并计算平均值;
2)吸水性能测试:根据中华人民共和国医药行业标准《接触性创面敷料试验方法第1 部分:液体吸收性》(YY/T 0471.1-2004)进行吸水性能测试。取氧化亚铜-氧化刺槐豆胶复合膜(长度*宽度*厚度:1.5cm*0.7cm*0.2cm);将样品称重记为m1,放入恒温37℃的模拟体液(溶液中含142mmol/L钠离子和2.5mmol/L的钙离子,离子含量相当于人体血清或创面渗出液,在容量瓶中用去离子水溶解8.298g氯化钠和0.3689g二水氯化钙并稀释至1L即得)中,30min后,用镊子夹住样品一角并悬挂30s,吸干水分后,称重记为m2,计算公式如(1)所示:
Figure BDA0003079536290000032
分别在0.5h,1h,2h,4h,6h,12h,24h,48h,72h将样品取出进行测试;
3)保湿能力:用皮肤水分测试仪测试肌肤的保湿度,在常温下25℃、40~60%RH进行测试,试验部位为正常健康女性小臂外侧肌肤,试验区域为5×5cm2,试验样品为5cm×5cm ×0.2cm,测试时间为0h、0.5h、1h、2h、4h、6h;
4)抗菌效果:采用抑菌圈法测定,测试菌种为大肠杆菌、绿脓杆菌、金黄色葡萄球菌枯草芽孢杆菌和白色念珠菌,方法步骤如下:配制LB培养液和LB培养基,复苏菌种,制备菌悬液(106cfu/ml),分别称量实施例1中的样品各5mg并经紫外灭菌处理,取200μL配制的菌悬液均匀涂布于LB培养基上,将配置好的样品等间距放置于涂布细菌、真菌的培养基上,每个培养基中放置三个试验样(实施例1中的各五组样品),将培养皿倒置于37℃的恒温培养箱中,细菌培养18h,真菌培养42h,取出培养皿,拍照并使用游标卡尺测量抑菌圈直径,分别继续培养36h后再次记录测量,记录结果;
根据相关标准,抑菌圈直径大于7mm则说明具有抗菌效果。
按上述测定方法得到的结果见表2~4;
表2:氧化亚铜-氧化刺槐豆胶和κ-C粉末的添加量对敷料耐水性能的影响
Figure BDA0003079536290000041
由表2中敷料样品的脱水收缩和吸水溶胀结果可知,随着氧化亚铜-氧化刺槐豆胶的增加,降低了κ-C的泌水性,敷料脱水收缩降低,同时,吸水溶胀性下降,主要是因为原因是 Cu2O填充在复合膜的孔隙中,导致复合膜吸水率下降,因此该组份添加量减少会导致吸水率降低,而两组实施例以实施例1(1-4)的复配比例2:1为最优比;
表3:氧化亚铜-氧化刺槐豆胶和κ-C粉末的添加量对敷料保湿性能的影响
Figure BDA0003079536290000042
由表3中的保湿性能结果可知,样品的保湿性能在4h内保持增加,4h后有脱水现象,同时,随着氧化亚铜-氧化刺槐豆胶和κ-C粉末的比例增加保持性能增加,主要由于氧化刺槐豆胶的增加降低了κ-C的泌水性,进而增加敷料的稳定性,当比例为2:1(1-4)时,两者的协同性最好。
表4:氧化亚铜-氧化刺槐豆胶和κ-C粉末的添加量对敷料抗菌效果(抑菌圈/mm)的影响
Figure BDA0003079536290000051
由表4的抗菌效果可知,实施例1中氧化亚铜-氧化刺槐豆胶和κ-C粉末的添加量比对该敷料的抗菌效果由显著的影响,其中可能得原因是敷料的抗菌效果主要由敷料基质中的氧化亚铜含量起主导作用,随着氧化亚铜-氧化刺槐豆胶含量的增加,氧化亚铜的抗菌效果增加,同时由于氧化刺槐豆胶和κ-C粉末的复配协同效应,该敷料基质结构的致密程度会影响氧化亚铜与外界细菌或真菌的接触面积;综合以上原因,实施例1中氧化亚铜-氧化刺槐豆胶和κ-C 粉末的添加量比为0.5~2.5:1,其中以2:1(1-4)制备得到敷料基质抗菌效果最佳,对细菌的抑制率较真菌更好,抑菌圈可达7.00mm以上,其中对革兰氏阴性和阳性菌中的大肠杆菌和金黄色葡萄球菌的抑制率最好,抑菌圈达到8.5mm以上,表明该敷料具备较好的抗菌效果,可同时减少防腐剂等成分的添加。
实施例2
按重量级百分比计,将1.33%氧化亚铜-氧化刺槐豆胶加入至去离子水中溶解,磁力搅拌逐渐加热升温至50℃,加入0.67%κ-C搅拌分散均匀继续升温至80~90℃,得到水凝胶基质,该温度范围下依次加入0.1~2%羟丙基淀粉、0.1~0.5%丁二醇和0.2%葡萄糖,其余为去离子水,并保温1.0h,使胶液充分溶胀,采用真空脱气装置对胶液进行高温脱气,除泡0.5 h,调节pH为7.3~7.4,并降温至50~60℃,静置24h,即得;
其中水凝胶基质、分散剂(羟丙基淀粉)、保湿剂(丁二醇)以及渗透压调节剂(葡萄糖)的添加量比为10:1~5:0.5~2.5:1,如表5所示:
表5:敷料各组分的添加量
Figure BDA0003079536290000052
对上述五组样品进行脱水收缩、吸水溶胀性、保湿能力的测定,其测定条件同实施例1,得到的结果见表6~7;
表6:各组分的添加量对敷料耐水性能的影响
Figure BDA0003079536290000061
表7:各组分的添加量对敷料保湿性能的影响
Figure BDA0003079536290000062
表6和表7结果显示,随着分散剂和保湿剂的添加,由于其均为羟基含量较多的物质成分,因此敷料的吸湿性增加;另一方面,随着分散剂和保湿剂的添加,保湿性能变好,其中分散剂为大分子多糖含有大量亲水性羟基基团,因此能够提高敷料与肌肤的贴合性,能够防止肌肤表面水分的散失。

Claims (4)

1.一种氧化亚铜-氧化刺槐豆胶抗菌敷料,其特征在于,所述的敷料由水凝胶基质、分散剂、保湿剂、渗透压调节剂组成;
所述的水凝胶基质为氧化亚铜-氧化刺槐豆胶与κ-C得到的复配物;
所述的分散剂为直链淀粉、羟丙基淀粉、羟丙基淀粉中的一种或组合;
所述的保湿剂为甘油、丁二醇、丙二醇中的一种或组合;
所述的渗透压调节剂为氯化钠、葡萄糖中的一种或组合;
所述的水凝胶基质结构示意式如(I)所示:
Figure FDA0003079536280000011
2.一种氧化亚铜-氧化刺槐豆胶抗菌敷料的制备方法,其特征在于,包括以下步骤:
按重量级百分比计,将0.2~2.0%氧化亚铜-氧化刺槐豆胶加入至去离子水中溶解,磁力搅拌逐渐加热升温至50℃,加入0.5~2%κ-C搅拌分散均匀继续升温至80~90℃,得到水凝胶基质,该温度范围下依次加入0.1~2%分散剂、0.1~0.5%保湿剂和0.1~0.5%渗透压调节剂,其余为去离子水,并保温1.0h,使胶液充分溶胀,采用真空脱气装置对胶液进行高温脱气,除泡0.5h,调节pH为7.3~7.4,并降温至50~60℃,静置24h,即得氧化亚铜-氧化刺槐豆胶抗菌敷料。
3.根据权利要求2所述的一种氧化亚铜-氧化刺槐豆胶抗菌敷料的制备方法,其特征在于,所述步骤中的氧化亚铜-氧化刺槐豆胶与κ-C的添加量比为0.5~2.5:1。
4.根据权利要求2所述的一种氧化亚铜-氧化刺槐豆胶抗菌膜的制备方法,其特征在于,所述步骤中水凝胶基质、分散剂、保湿剂、渗透压调节剂的添加量比可为10:1~5:0.5~2.5:1。
CN202110562568.2A 2021-05-24 2021-05-24 一种氧化亚铜-氧化刺槐豆胶抗菌敷料 Withdrawn CN113274540A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110562568.2A CN113274540A (zh) 2021-05-24 2021-05-24 一种氧化亚铜-氧化刺槐豆胶抗菌敷料

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110562568.2A CN113274540A (zh) 2021-05-24 2021-05-24 一种氧化亚铜-氧化刺槐豆胶抗菌敷料

Publications (1)

Publication Number Publication Date
CN113274540A true CN113274540A (zh) 2021-08-20

Family

ID=77280919

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110562568.2A Withdrawn CN113274540A (zh) 2021-05-24 2021-05-24 一种氧化亚铜-氧化刺槐豆胶抗菌敷料

Country Status (1)

Country Link
CN (1) CN113274540A (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH258213A (fr) * 1945-06-15 1948-11-30 Gignoux & Cie Societe A Respon Procédé pour l'obtention d'un fongicide contenant de l'oxyde cuivreux.
CN106947095A (zh) * 2017-03-29 2017-07-14 邱发龙 一种用于伤口愈合抑菌型水凝胶的制备方法
CN112300449A (zh) * 2020-11-03 2021-02-02 赵书敏 一种改性刺槐豆胶-kappa型卡拉胶凝胶及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH258213A (fr) * 1945-06-15 1948-11-30 Gignoux & Cie Societe A Respon Procédé pour l'obtention d'un fongicide contenant de l'oxyde cuivreux.
CN106947095A (zh) * 2017-03-29 2017-07-14 邱发龙 一种用于伤口愈合抑菌型水凝胶的制备方法
CN112300449A (zh) * 2020-11-03 2021-02-02 赵书敏 一种改性刺槐豆胶-kappa型卡拉胶凝胶及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
胡英: ""氧化亚铜/微生物纤维素复合膜制备及其结构性能研究"", 《中国博士学位论文全文数据库 (工程科技Ⅰ辑)》, 15 March 2020 (2020-03-15), pages 016 - 43 *

Similar Documents

Publication Publication Date Title
CN111150880A (zh) 一种抗菌复合水凝胶及其制备方法
CN103463124B (zh) 一种细菌纤维素壳聚糖复合凝胶及其制备与体表创面愈合的应用
CN109369948B (zh) 一种细菌纤维素/聚乙烯醇抗菌水凝胶及其制备方法和应用
CN105251045B (zh) 一种含岩藻多糖的生物医用水凝胶及其制备方法
CN102675651B (zh) 抗菌敷料用壳聚糖水凝胶的制备方法
CN111558081B (zh) 一种制备单宁酸改性双层水凝胶的方法
CN112851951B (zh) 一种接枝ε-聚赖氨酸的双醛基壳聚糖及其制备方法和应用
CN113637183A (zh) 改性石墨烯负载纳米银/聚乙烯醇抗菌水凝胶及其制备方法
CN104546717A (zh) 一种高抗菌壳聚糖成膜喷剂及其制备方法
Liu et al. A lignocellulose-based nanocomposite hydrogel with pH-sensitive and potent antibacterial activity for wound healing
CN107281541A (zh) 一种医用温敏性水凝胶的制备方法
CN106580871B (zh) 一种阴道凝胶及其制备方法
US20170050172A1 (en) Hydrogel Composition
CN105641735B (zh) 一种抗菌性多糖止血棉基纱布的制备方法
CN112402688A (zh) 一种生物相容性且抗菌的快速止血纳米材料及其制备方法
CN106344954A (zh) 一种生物抗菌细菌纤维素敷料及其制备方法
CN102726395A (zh) 戊二醛交联壳聚糖在抑制洋葱伯克氏菌群生长中的应用
CN107915850B (zh) 含硒壳聚糖水凝胶及其制备、降解方法和应用
CN104984456A (zh) 一种抗菌型聚氨酯类医疗器械、其制备方法及抗菌型留置针外周导管
CN100390351C (zh) 壳聚糖多孔膜包覆的抗菌活性炭纤维及其制备方法
Zhang et al. Lignin-containing hydrogels: Transforming a low-value byproduct to absorbents, wound dressings and strain sensors
CN113274540A (zh) 一种氧化亚铜-氧化刺槐豆胶抗菌敷料
CN113679881A (zh) 一种具有抗菌性能的医用敷料及其制备方法
CN111514371B (zh) 一种表面负载纳米银的双层水凝胶的制备方法
CN111973801A (zh) 一种抗炎修复的水凝胶及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20210820